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Abstract
AIM: To study the practical applicability of the Ame-
rican Society for Gastrointestinal Endoscopy guidelines 
in suspected cases of choledocholithiasis.
METHODS: This was a retrospective single center 
study, covering a 4-year period, from January 2010 
to December 2013. All patients who underwent 
endoscopic retrograde cholangiopancreatography 
(ERCP) for suspected choledocholithiasis were included. 
Based on the presence or absence of predictors of 
choledocholithiasis (clinical ascending cholangitis, 
common bile duct (CBD) stones on ultrasonography 
(US), total bilirubin > 4 mg/dL, dilated CBD on US, 
total bilirubin 1.8-4 mg/dL, abnormal liver function 
test, age > 55 years and gallstone pancreatitis), 
patients were stratified in low, intermediate or high 
risk for choledocholithiasis. For each predictor and 
risk group we used the χ 2 to evaluate the statistical 
associations with the presence of choledocolithiasis 
at ERCP. Statistical analysis was performed using 
SPSS version 21.0. A P  value of less than 0.05 was 
considered statistically significant. 
RESULTS: A total of 268 ERCPs were performed for 
suspected choledocholithiasis. Except for gallstone 
pancreatitis (P  = 0.063), all other predictors of cho-
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ledocholitiasis (clinical ascending cholangitis, P  = 0.001; 
CBD stones on US, P  ≤ 0.001; total bilirubin > 4 mg/
dL, P  = 0.035; total bilirubin 1.8-4 mg/dL, P = 0.001; 
dilated CBD on US, P  ≤ 0.001; abnormal liver function 
test, P  = 0.012; age > 55 years, P = 0.002) showed a 
statistically significant association with the presence of 
choledocholithiasis at ERCP. Approximately four fifths 
of patients in the high risk group (79.8%, 154/193 
patients) had confirmed choledocholithiasis on ERCP, 
vs  34.2% (25/73 patients) and 0 (0/2 patients) in the 
intermediate and low risk groups, respectively. The 
definition of “high risk group” had a sensitivity of 86%, 
positive predictive value 79.8% and specificity 56.2% 
for the presence of choledocholithiasis at ERCP. 
CONCLUSION: The guidelines should be considered 
to optimize patients’ selection for ERCP. For high risk 
patients specificity is still low, meaning that some 
patients perform ERCP unnecessarily. 
Key words: Choledocholithiasis; Endoscopic retrograde 
cholangiopancreatography; Cholangitis; Common bile 
duct stones; Dilated common bile duct 
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The American Society for Gastrointestinal 
Endoscopy (ASGE) proposes a stratification of patients 
according to the risk for choledocholithiasis, influencing 
subsequent management. Our study shown that the 
risk stratification, according to ASGE guidelines, may 
improve risk estimation of choledocholithiasis and 
should be considered to optimize patients’ selection 
for endoscopic retrograde cholangiopancreatography 
(ERCP). However, even in the “high risk group” the 
specificity was low. Thus, at this point, it seems 
advisable that also “high risk” patients undergo further 
testing before being submitted to ERCP, similarly 
to those patients with “intermediate risk”, while for 
patients with “low-risk” of choledocholithiasis a watchful 
waiting strategy seems adequate.
Magalhães J, Rosa B, Cotter J. Endoscopic retrograde cho-
langiopancreatography for suspected choledocholithiasis: 
From guidelines to clinical practice. World J Gastrointest 
Endosc 2015; 7(2): 128-134  Available from: URL: http://www.
wjgnet.com/1948-5190/full/v7/i2/128.htm  DOI: http://dx.doi.
org/10.4253/wjge.v7.i2.128
INTRODUCTION
Choledocholithiasis is the most common cause of bili-
ary obstruction. Approximately 5% to 22% of the 
Western population has gallstones[1] and common bile 
duct stones occur in 8%-20%[2,3] of those patients. 
Patients suspected of having choledocholithiasis are 
diagnosed with a combination of laboratory tests and 
imaging studies[4]. The first imaging study obtained 
is typically a transabdominal ultrasonography (US). 
When the ultrasound findings are not enough for a 
diagnosis a magnetic resonance cholangiopancrea-
tography (MRCP) or an endoscopic ultrasound (EUS) 
should be considered. 
The diagnosis of choledocholithiasis usually should 
be followed by some therapeutic intervention to re-
move the stones[4-7]. Endoscopic retrograde cholan-
giopancreatography (ERCP) is the standard method 
for the diagnosis and therapy of bile duct stones, 
however it is an invasive procedure not free of com-
plications[8-11]. 
According to the results of laboratory tests and 
US, the American Society for Gastrointestinal Endos-
copy (ASGE) proposes to stratify a patient in low, 
intermediate or high risk for choledocholithiasis. Sub-
sequent management will vary depending on the pa-
tient’s level of risk[12]. The purpose of this study was 
to evaluate the practical applicability of the American 
Society for Gastrointestinal Endoscopy guidelines in a 
population of patients undergoing ERCP for suspected 
choledocholithiasis. 
MATERIALS AND METHODS
Patients
We performed a retrospective single center study, 
covering a 4-year period, from January 2010 to 
December 2013. Patients referred for ERCP for sus-
pected bile duct lithiasis were consecutively included. 
Patients presenting for stent exchange or follow-up of 
known and incompletely removed stones on previous 
ERCP were excluded. 
Clinical data recorded from disease onset (age, 
gender, symptoms at presentation, laboratorial val-
ues) to the time of the ERCP (therapeutic procedures 
and related complications) were collected. 
Predictors of choledocholithiasis
According to ASGE guidelines[12], cholangitis, total 
bilirubin > 4 mg/dL and common bile duct (CBD) 
stone on US were considered very strong predic-
tors. Total bilirubin 1.8-4 mg/dL and dilated CBD on 
US were considered strong predictors and abnormal 
liver biochemical tests, age > 55 years and gallstone 
pancreatitis were considered moderate predictors. 
Patients with strong predictors or any very strong 
predictor were considered at high risk for choledocho-
lithiasis. Patients without any predictor and all other 
patients were considered low and intermediate risk 
for choledocholithiasis, respectively. The diagnosis of 
cholangitis was established by the presence of Char-
cot’s triad (fever, abdominal pain and jaundice). The 
diagnosis of CBD stone on US was considered when 
an intraductal echogenic focus with distal acoustic 
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shadow was identified. Dilated CBD on US was con-
sidered when bile duct diameter was > 6 mm in a 
patient without cholecystectomy. Abnormal liver bio-
chemical tests were considered when aspartate ami-
notransferase (AST), alanine aminotransferase (ALT) 
and alkaline phosphatase (AP) presented elevated 
laboratory values, considering the reference lab val-
ues in our institution. Gallstone pancreatitis was con-
sidered when patients presented with abdominal pain 
(epigastric pain often radiating to the back), lipase 
(or amylase activity) at least 3 times higher than the 
upper limit of normal, stones or biliary sludge within 
gallbladder and no history of alcohol abuse.
Endoscopic retrograde cholangiopancreatography 
procedure
Every ERCP was performed using Olympus® TJF 160 
VR or TJF 145 side-viewing endoscopes. All patients 
provided written consent to undergo ERCP and were 
informed of the risks and benefits of the procedure. 
Patients were under propofol sedation assisted by 
an anaesthesiologist. Stone size and number were 
documented on the initial diagnostic cholangiogram at 
ERCP. Endoscopic sphincterotomy was performed over 
a guide wire. Some patients underwent papillary bal-
loon dilation using a through-the-scope balloon cath-
eter for oesophageal/pyloric dilation, gradually inflated 
to 12-18 mm according to the size of the largest stone 
and the maximal diameter of the distal bile duct on 
the cholangiogram. Stones were removed using a re-
trieval balloon catheter and/or a Dormia basket. When 
necessary, mechanical lithotripsy was performed to 
fragment the stones prior to removal. Complete clear-
ance of the bile duct was documented with a balloon 
catheter cholangiogram at the end of the procedure. 
In the case of residual lithiasis, a biliary 7 Fr double 
pigtail plastic stent was placed and a second ERCP was 
planned within 10-12 wk. At the end of each ERCP, 
100 mg rectal indomethacin was routinely given, to 
prevent post-ERCP pancreatitis. Prophylactic antibiot-
ics were not routinely administered.
Statistical analysis
Statistical analysis was performed using SPSS version 
21.0 (SPSS® Inc., Chicago, IL, United States). 
Quantitative data were described as mean ± SD 
and qualitative data as proportions. For each predictor 
and risk group the χ 2 was used to access differences 
between presence vs absence of choledocolithiasis on 
ERCP. A P value < 0.05 was considered statistically 
significant.
For each risk group and their predictors the sensi-
tivity, specificity, positive predictive values (PPV) and 
negative predictive value (NPV) were assessed.
RESULTS
From January 2010 to December 2013, a total of 268 
patients were referred for ERCP for suspected cho-
ledocholithiasis. Patients included in our study were 
predominantly female (60.1%), with a mean age of 
66.8 ± 16.8 years. Choledocholithiasis was present in 
179 ERCPs (66.8%). The predictors more often seen 
in our patients were the presence of abnormal liver 
biochemical tests (86.2%), age > 55 years (73.5%) 
and dilated CBD on US (72.8%). Main clinical features 
of the study population are shown in Table 1.
Predictors of choledocholithiasis
Except for gallstone pancreatitis (P = 0.063), all other 
predictors showed a statistically significant difference 
between presence vs absence of choledocholithiasis 
on ERCP (cholangitis, P = 0.001; CBD stone on US, P < 
0.001; total bilirubin > 4 mg/dL, P = 0.035; total bili-
rubin 1.8-4 mg/dL, P = 0.001; dilated CBD on US, P < 
0.001; abnormal liver function test, P = 0.012; age > 
55 years, P = 0.002) (Table 2).
The risk of choledocholithiasis, as shown by odds 
ratio, was increased for patients who presented with 
cholangitis (OR: 6.48, 95%CI: 1.93-21.80), common 
bile duct stone on US (OR: 11.25, 95%CI: 5.32-23.81), 
total bilirubin > 4 mg/dL (OR: 1.79, 95%CI: 
1.04-3.08), total bilirubin 1.8-4 mg/dL (OR:3.15, 
95%CI: 1.63-6.08), dilated common bile duct on US 
(OR:5.06, 95%CI: 2.85-8.99), abnormal liver function 
test (OR:2.43, 95%CI: 1.20-4.90) and age > 55 years 
(OR:2.37, 95%CI: 1.36-4.15) (Table 2).
Risk group for choledocholithiasis
Of the 268 patients included in this study, 72% were 
stratified into the high risk group. Of the remain-
ing patients, 27.2% e 0.8% were stratified into the 
intermediate and low risk groups, respectively. Ap-
proximately four fifths of patients in the high risk 
group (79.8%, 154/193 patients) had confirmed 
choledocholithiasis on ERCP. The presence of cho-
ledocholithiasis was identified in 34.2% (25/73) of 
intermediate risk patients. Any patient into the low 
risk group had choledocholithiasis on ERCP. There 
was a statistically significant association between 
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Table 1  Baseline characteristics of the study population  n  (%)
Variable Total (n  = 268)
Gender, female 161 (60.1)
Age, mean ± SD 66.8 ± 16.8
Very strong predictors
   Clinical ascending cholangitis   36 (13.4)
   Common bile duct stone on US 109 (40.7)
   Total bilirubin > 4 mg/dL 102 (38.1)
Strong predictors
   Total bilirubin 1.8-4 mg/dL 84 (31.3)
   Dilated common bile duct on US 195 (72.8)
Moderate predictors
   Abnormal liver function test 231 (86.2)
   Age > 55 yr 197 (73.5)
   Gallstone pancreatitis   63 (23.5)
US: Ultrasonography. 
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high risk has > 50% of probability of choledocho-
lithiasis[12]. In our study, patients stratified as high 
risk following ASGE criteria had 79.8% probability of 
choledocholithiasis. These results are consistent with 
those presented in the study by Rubin et al[13]. All the 
very strong predictors (clinical ascending cholangitis, 
CBD stones on US or total bilirubin > 4 mg/dL) pre-
sented a statistically significant association with the 
presence of choledocholithiasis. The combination of 
any of two or three very strong predictors increased 
the probability of choledocholithiasis for 87.9% and 
100%, respectively. 
Transabdominal ultrasound is the most commonly 
used initial imaging modality for suspected biliary 
stones. In our study, the presence of CBD stones de-
tected during the US evaluation presented an OR of 
11.25 for choledocholithisis. The diagnosis of choledo-
cholithiasis is often difficult, with the sensitivity for 
the detection of CBD stones by US ranging from 20% 
to 80%[14]. The diagnostic accuracy of US is opera-
tor dependent but it is also influenced by some clini-
cal features of patients (shadowing from bowel gas, 
overweight and stone size)[14].
In our study, the combination of strong predic-
tors (dilated CBD on US, total bilirubin 1.8-4 mg/dL) 
presented 83.3% of probability of choledocholithiasis 
confirmed at ERCP. Strong predictors presented a sta-
the presence of choledocholithiasis on ERCP and the 
risk group (P < 0.001) (Table 3). The odds ratio (OR) 
for choledocholithiasis in high risk patients was 7.89 
(95%CI: 4.36-14.32). The combination of any two 
or all very strong predictors elevated the probability 
of choledocholithiasis for 87.9% (51/58) and 100% 
(9/9), respectively. The combination of both strong 
predictors presented 83.3% (50/60) of probability of 
choledocolithiasis.
Sensitivity, specificity, positive predictive values and 
negative predictive values for choledocolithiasis
Cholangitis was the parameter that had the higher 
specificity (96.6%), however for the same parameter 
the sensitivity was low. Total bilirubin > 4 mg/dL or 
the presence of CBD stones on US also presented a 
good specificity (89.9% and 70.8%, respectively). 
The PPV was high for very strong predictors, mainly 
clinical ascending cholangitis (PPV 91.7%) and CBD 
stones on US (PPV 91.7%). The high risk group had 
a high sensitivity (86%) and PPV (79.8%), but low 
specificity (56.2%) for the presence of CBD stones 
(Table 4).
DISCUSSION
According to ASGE guidelines, a patient stratified as 
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Table 2  Predictors of choledocholithiasis - univariate analysis  n  (%)
Variable Choledocholithiasis on ERCP No Choledocholithiasis on ERCP OR 95%CI P  value
Very strong predictors
   Clinical ascending cholangitis   33 (91.7) 3 (8.3)   6.48 1.93-21.80    0.001
   Common bile duct stone on US 100 (91.7) 9 (8.3) 11.25 5.32-23.81 < 0.001
   Total bilirubin > 4 mg/dL   76 (74.5) 26 (25.5)   1.79 1.04-3.08    0.035
Strong predictors
   Total bilirubin 1.8-4 mg/dL   63 (75.0) 21 (25.0)   3.15 1.63-6.08    0.001
   Dilated common bile duct on US 150 (76.9) 45 (23.1)   5.06 2.85-8.99 < 0.001
Moderate predictors
   Abnormal liver function test 161 (69.7) 70 (30.3)   2.43 1.20-4.90    0.012
   Age > 55 yr 142 (72.1) 55 (27.9)   2.37 1.36-4.15    0.002
   Gallstone pancreatitis   36 (57.2) 27 (42.8)   0.58 0.32-1.03    0.063
ERCP: Endoscopic retrograde cholangiopancreatography; US: Ultrasonography.
Table 3  Risk group for choledocholithiasis - univariate analysis  n  (%)
Variable Total Choledocholithiasis on ERCP No Choledocholithiasis on ERCP P value
High risk group 193 (72.0)  154 (79.8)   39 (20.2) < 0.001
Intermediate risk group   73 (27.2)    25 (34.2)   48 (65.8)
Low risk group 2 (0.8) 0 (0)    2 (100)
Very strong predictors
   None   97 (36.2)   39 (40.2)    58 (59.8) < 0.001
   One 104 (38.8)   80 (76.9)    24 (23.1)
   Two   58 (21.6)   51 (87.9)      7 (12.1)
   Three  9 (3.4)   9 (100) 0 (0)
Strong predictors
   None 27 (16.4)    3 (11.1)    24 (88.9) < 0.001
   One 78 (47.3)  50 (64.1)    28 (35.9)
   Two 60 (36.4)  50 (83.3)    10 (16.7)
ERCP: Endoscopic retrograde cholangiopancreatography. 
Magalhães J et al . Endoscopic retrograde cholangiopancreatography for suspected choledocholithiasis
tistically significant association with the presence of 
choledocholithiasis, which is in line with other previ-
ously published data[15-18]. The OR for choledocholithi-
asis in a patient with a CBD dilation was 5.06. How-
ever, the CBD dilation should always be interpreted 
according to patient characteristics, particularly pre-
vious cholecystectomy and age[19-21]. Previous stud-
ies[15-17,22,23] have reported some utility of serum biliru-
bin levels as a predictor of CBD stones. In this study, 
a bilirubin value between 1.8-4 g/dL had an OR of 3.15 
and a specificity of 66.6% for choledocolithiasis. The 
specificity increased to 70% when the bilirrubin value 
was > 4 mg/dL. These results are in agreement with 
those previously reported by ASGE guidelines[12].
Individually, moderate predictors, such as abnor-
mal liver function test and age > 55 years, presented 
a statistically significant association with the presence 
of choledocholithiasis in our series and a sensitivity of 
89.9% and 79.3% for the prediction of choledocholi-
thiasis on ERCP. In a study by Barkun et al[16], abnor-
mal liver function tests, such as alkaline phosphatase 
> 300 units/L and AST > 120 units/L present a sensi-
tivity of 79% and 81% to predict choledocholithiasis, 
respectively. At the same study, age > 55 years, only 
presented a sensitivity of 57%, however, when com-
bined with other predictors (elevated bilirubin and 
CBD dilation on US) the model predicted with 94% of 
probability the presence of choledocholithiasis. 
As previously reported by other authors[13,24], also 
in our results the diagnosis of gallstone pancreatitis 
was not related with the presence of choledocholithia-
sis at ERCP (P > 0.05). Stone size may be an expla-
nation, as larger stones are less likely to migrate[24] 
and the small gallstones, that most commonly are 
the source of pancreatitis[25], frequently pass spon-
taneously. Some studies have reported that in the 
absence of cholangitis, patients with gallstone pan-
creatitis do not benefit from early ERCP[26,27]. 
In patients stratified into the intermediate and low 
risk group, the probability of choledocholithiasis is 
10%-50% and < 10%, respectively[12]. In this study, 
the probability of choledocholithiasis was 34.2% 
(25/73) and 0 (0/2) for intermediate and low risk 
groups, respectively. For these risk groups the sen-
sitivity, specificity, PPV and NPV did not show values 
with clinical interest. In the intermediate risk group, 
ASGE guidelines[12] recommended less invasive op-
tions for detecting choledocholithiasis, such as MRCP 
or EUS. The two techniques showed a good sensitivity 
and specificity for choledocholithiasis[28,29], so deciding 
which test should be performed first depends on vari-
ous factors such as availability, cost, patient-related 
factors and the suspicion for a small stone. Because 
it is noninvasive, MRCP is the first test performed to 
look for CBD stones. However, for small CBD stones (< 
5 mm) the sensitivity of MRCP is lower[30], so, if the 
MRCP is negative, but the suspicion for a common 
bile duct stone remains moderate to high, EUS is an 
appropriate next step. 
In conclusion, our study confirms that the com-
bination of choledocolithiasis predictors, according 
to ASGE guidelines[12], enables risk stratification of 
patients based on the likelihood for the presence of 
choledocholithiasis. However, for high risk patients 
the specificity was still low (56.2%), with 39 patients 
(20%) false positive, meaning that a significant pro-
portion of patients will be submitted to ERCP unnec-
essarily. In the future, the inclusion of new predictors 
or different combinations of previous predictors will 
be essential to improve the classification of patients 
as high risk, obviating the need of other imaging tests 
(MRCP/EUS) before ERCP. However, at this point, it 
seems advisable that also “high risk” patients un-
dergo further testing with MRCP and/or EUS before 
being submitted to ERCP, similarly to those patients 
with “intermediate risk”, while for patients with “low-
risk” of choledocholithiasis a watchful waiting strategy 
seems adequate.
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Background
Patients suspected of having choledocholithiasis are diagnosed with a 
combination of laboratory tests and/or imaging studies. Endoscopic retrograde 
cholangiopancreatography (ERCP) has been established as the standard 
method for the management of bile duct stones, but it may be associated 
with substantial morbidity and mortality. In the evaluation of suspected 
choledocolithiasis, the American Society for Gastrointestinal Endoscopy (ASGE) 
proposes to stratify a patient as high risk, intermediate risk or low risk for having 
choledocholithiasis. Subsequent management will vary depending on the 
patient’s level of risk.
Research frontiers
In this study, the authors aimed to assess the practical applicability and to 
validate the current ASGE guidelines in a population of patients undergoing 
ERCP for suspected choledocholithiasis.
Innovations and breakthroughs
The study confirms that the combination of choledocolithiasis predictors, 
according to ASGE guidelines may improve risk estimation of choledo­
cholithiasis and should be considered to optimize patients’ selection for ERCP. 
However, even in the “high risk group” the specificity was low (56.2%), meaning 
that a significant proportion of patients will still perform ERCP unnecessarily.
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Table 4  Sensitivity, specificity, positive predictive values and 
negative predictive values for choledocolithiasis
Variable Sensitivity Specificity PPV NPV
Very strong predictors
   Clinical ascending cholangitis 18.4 96.6 91.7 37.0
   Common bile duct stone on US 55.9 89.9 91.7 50.3
   Total bilirubin > 4 mg/dL 42.5 70.8 74.5 37.8
Strong predictors
   Total bilirubin 1.8-4 mg/dL 61.1 66.6 75 51.2
   Dilated common bile duct on US 83.8 49.4 76.9 60.3
Moderate predictors
   Abnormal liver function test 89.9 21.3 69.7 51.3
   Age > 55 yr 79.3 38.2 72.1 47.9
   Gallstone pancreatitis 20.1 69.7 57.1 30.2
   High risk group 86 56.2 79.8 66.7
   Intermediate risk group 13.9 46 34,2 21
PPV: Positive predictive values; NPV: Negative predictive values; US: 
Ultrasonography.
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Applications
The results of this study suggest that the inclusion of new predictors of 
choledocholithisis or different combinations of previous predictors will be 
essential to improve the classification of patients as high risk, obviating the need 
of other imaging tests before endoscopic retrograde cholangiopancreatography. 
Thus, at this point, it seems advisable that also “high risk” patients undergo 
further testing before being submitted to ERCP, similarly to those patients with 
“intermediate risk”, while for patients with “low­risk” of choledocholithiasis a 
watchful waiting strategy seems adequate.
Terminology
Choledocholithiasis is defined as the occurrence of stones in the bile duct 
and has a propensity for life­threatening complications such as cholangitis 
and acute pancreatitis. Endoscopic retrograde cholangiopancreatography is 
a technique that combines the use of endoscopy and fluoroscopy to diagnose 
and treat problems of the biliary or pancreatic ductal systems. It has evolved 
from a diagnostic procedure to an almost exclusively therapeutic technique.
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